These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26382234)

  • 1. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
    Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
    Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
    Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
    Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
    Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.
    Tebbens RJD; Hampton LM; Wassilak SGF; Pallansch MA; Cochi SL; Thompson KM
    J Vaccines Vaccin; 2016 Oct; 7(5):. PubMed ID: 28690915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    PLoS One; 2015; 10(6):e0130123. PubMed ID: 26068928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.